A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 inPatients with Mature B-Cell Malignancies
Contact:
NCT Number:
Protocol:
AAAT5414
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to look at the safety and tolerability of an investigational anticancer drug currently known as BGB-11417. This study aims to determine the range of BGB-11417 doses that can safely be used, the safest dosing schedule to minimize side effects when first taking BGB-11417, what side effects may be experienced when taking this drug, how your body processes this drug, and if this drug is effective against your cancer.
Are you Eligible? (Inclusion Criteria)
- Provision of signed and dated written informed consent prior to any study specific procedures, sampling, or analyses
- Age 18 years or older
- Confirmed diagnosis of one of the following
Specialty Area(s)
Leukemia
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
